scholarly journals Efficacy of combined therapy with intravenous sodium ozagrel and heparin for acute thrombotic and hemodynamic stroke in elderly patients.

Nosotchu ◽  
1996 ◽  
Vol 18 (2) ◽  
pp. 118-123
Author(s):  
Masayuki Ueda ◽  
Makoto Hamamoto ◽  
Takehiko Nagao ◽  
Tokuzo Miyazaki ◽  
Akiro Terashi
Keyword(s):  
Elderly Patients ◽  
Combined Therapy ◽  
Hemodynamic Stroke ◽  
Intravenous Sodium

scholarly journals Short-term efficacy of a fixed association of Palmitoylethanolamide and other phytochemicals as add-on therapy in the management of chronic pain in elderly patients: a real-world retrospective study

2018 ◽  
Vol 4 (1) ◽  
Author(s):  
Walter Gianni ◽  
Massimo Di Carlo ◽  
Luciano Colangelo ◽  
Giada Della Grotta ◽  
Chiara Sonato ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Elderly Patients ◽  
Combined Therapy ◽  
Treatment Withdrawal ◽  
Fixed Dose ◽  
Moderate Degree ◽  
Short Term ◽  
Term Efficacy ◽  
Small Subgroup ◽  
Subjective Belief

Phytochemicals are promising adjuvant agents for the treatment of pain. This study aimed to explore the short-term efficacy and safety of a fixed-dose combined therapy with Palmitoylethanolamide and other phytochemicals as add-on therapy in elderly patients. Data on 47 elderly patients with non-oncologic chronic pain of mild-moderate degree were analyzed in a retrospective, descriptive, no-profit, double-center realworld study. Patients were administered the combined phytochemical therapy for 6 weeks, in addition to analgesics administered when needed. Patients showed a reduction in pain intensity both in mixed /nociceptive and in neuropathic pain and improvements in functional abilities, quality of life, and in the subjective belief about the efficacy of treatment. These results were also observed in the small subgroup of patients in monotherapy with phytochemicals (n=13). No adverse event led to treatment withdrawal. This exploratory study suggests that phytochemicals may represent an effective source of analgesics to be added to chemically synthesized drugs, therefore reducing the need of their up-titration and the risk of toxicity. These data must be considered as preliminary and need to be tested in randomized trials.

scholarly journals Effect of vertigo on the quality of life of elderly patients with hypertensive encephalopathy

2015 ◽  
pp. 18-20
Author(s):  
V.V. Yavorsky
Keyword(s):  
Quality Of Life ◽  
Elderly Patients ◽  
Combined Therapy ◽  
Hypertensive Encephalopathy ◽  
Cranial Cavity ◽  
Venous Outflow ◽  
Treatment Groups ◽  
Betahistine Dihydrochloride ◽  
Accompanying Symptoms

Combined betahistine dihydrochloride-based therapy improved the performance of scales characterizing the vertigo along with the accompanying symptoms. The effect is comparable to the treatment groups of elderly patients with hypertensive encephalopathy. Vertigo is caused by abnormalities of venous outflow from the cranial cavity due to the increase of arterial pressure, which suggested the use of combined therapy.

scholarly journals Clinical experience with piribedil in chronic cerebrovascular disease with cognitive impairment

2019 ◽  
Vol 11 (4) ◽  
pp. 100-103
Author(s):  
E. V. Moroz ◽  
T. A. Zakharycheva ◽  
M. V. Antonyuk
Keyword(s):  
Cognitive Impairment ◽  
Elderly Patients ◽  
Cerebrovascular Disease ◽  
Cognitive Functions ◽  
Combined Therapy ◽  
Lipid Lowering ◽  
Control Group ◽  
Good Tolerability ◽  
Before And After

Objective: to evaluate the effect of piribedil on cognitive functions in elderly patients with chronic cerebrovascular disease (CCVD) and cognitive impairment (CI). Patients and methods. A total of 67 patients aged 60-75 years with CCVD and CI were examined. A control group included 32 patients who had received basic therapy with antihypertensive and, if indicated, lipid-lowering and antithrombotic drugs. A study group consisted of 35 patients who additionally took piribedil 50 mg after evening meals for 3 months. Neuropsychological examination was made before and after a treatment cycle. Results and discussion. After 3 months, only the piribedil group showed a significant neuropsychological improvement (p<0.05-0.001). There were statistically significant differences in the measures of short-term (5.9±0.5 and 4.27±0.5 words; p<0.05) and long-term (6.4±0.8 and 4.16±0.5 words; p<0.05) memories, correction task (38.4±0.8 and 49.1±0.1 errors; p<0.001), attentiveness (421.0±0.9 and 406.0±0.6 sec; p<0.001), and work efficiency (16.3±0.9 and 12.3±1.2 sec; p<0.05). The investigation revealed that the drug had a good tolerability, neither adverse events nor drug-drug interactions. Conclusion. When used in CCVD and CI, piribedil 50 mg once daily for 3 months is able to improve cognitive functions in elderly patients, which indicates that it is feasible to use the drug in combined therapy with essential (antihypertensive, lipid-lowering, antithrombotic) medicines.

Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients

2013 ◽  
Vol 118 (4) ◽  
pp. 786-798 ◽  
Author(s):  
Shota Tanaka ◽  
Fredric B. Meyer ◽  
Jan C. Buckner ◽  
Joon H. Uhm ◽  
Elizabeth S. Yan ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Adjuvant Treatment ◽  
Karnofsky Performance Status ◽  
Combined Therapy ◽  
Performance Status ◽  
Progression Free Survival ◽  
Postoperative Hemorrhage ◽  
Neurological Deficits ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma

Object Optimum management for elderly patients with newly diagnosed glioblastoma (GBM) in the temozolomide (TMZ) era is not well defined. The object of this study was to clarify outcomes in this population. Methods The authors retrospectively reviewed 105 consecutive cases involving elderly patients (age ≥ 65 years) with newly diagnosed GBM who were treated at the Mayo Clinic between 2003 and 2008. Results The patients' median age was 74 years (range 66–87 years), and the median Karnofsky Performance Status (KPS) score was 80 (range 40–90). Half of the patients underwent biopsy and half underwent resection. Patients with deep-seated lesions (19 patients [18%]) or multifocal lesions (34 patients [32%]) were more likely to have biopsy than resection (p = 0.0001 and 0.0009, respectively). New persistent neurological deficits developed in 7 patients (6.7%). Postoperative hemorrhage occurred in 6 patients (5.7%), all of whom underwent biopsy. Complete follow-up data regarding adjuvant treatment was available in 84 patients. Forty-one (49%) were treated with chemotherapy (mostly TMZ) and radiation therapy (RT), and 23 (27%) with RT alone. Nineteen (23%) received only palliative care after surgery (more common with biopsy, p = 0.03). Chemotherapy complications occurred in 28.6% (Grade 3 or 4 hematological complications in 11.9%). The median values for progression-free survival (PFS) and overall survival (OS) were 3.5 and 5.5 months. In a multivariate analysis, younger age (p = 0.03, risk ratio [RR] 0.34, 95% CI 0.13–0.89), single lesion (p = 0.02, RR 0.51, 95% CI 0.30–0.89), resection (p = 0.04, RR 0.54, 95% CI 0.31–0.94), and adjuvant treatment (p = 0.0001, RR 0.24, 95% CI 0.11–0.49) were associated with better OS. Only adjuvant treatment was significantly associated with prolonged PFS (p = 0.0007, RR 0.27, 95% CI 0.13–0.57). With combined therapy with resection, RT, and chemotherapy, the median PFS and OS were 8 and 12.5 months, respectively. Conclusions The prognosis for GBM worsens with increasing age in elderly patients. With important risks, resection and adjuvant treatment are associated with prolonged survival. Although selection bias cannot be excluded in this retrospective study, advanced age alone should not necessarily preclude optimal resection followed by adjuvant radiochemotherapy.

Combination Risperidone and SSRI–Induced Serotonin Syndrome

2003 ◽  
Vol 37 (3) ◽  
pp. 388-391 ◽  
Author(s):  
Shyam D Karki ◽  
Gule-Rana Masood
Keyword(s):  
Emergency Department ◽  
Nursing Home ◽  
Elderly Patients ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Syndrome ◽  
Combined Therapy ◽  
Drug Event ◽  
White Female ◽  
Medication History ◽  
Acute Changes

OBJECTIVE: To report 2 cases of serotonin syndrome associated with combined therapy of risperidone and selective serotonin-reuptake inhibitors (SSRIs) in elderly patients. CASE SUMMARIES: An 86-year-old white man was admitted to the emergency department because of increased confusion and generalized weakness over the past several days. His medication history indicated paroxetine 10 mg/d and risperidone 0.25 mg/d. The patient's confusion worsened and underwent acute changes that resembled delirium. He was placed in a geri chair and he became extremely agitated. He was then treated with escalating doses of risperidone. The patient died on day 5 of admission, at which time he was being treated with risperidone 2–3 mg/d. A 78-year-old white female nursing home resident was admitted to the emergency department because of increased confusion and generalized weakness. She was being treated with paroxetine for depression and risperidone for agitation. Her risperidone dose was increased to manage agitation. The patient's agitation worsened with increasing doses of risperidone; she developed tremor, dizziness, and muscle incoordination. After psychopharmacologic consultation, the risperidone and paroxetine were discontinued and she was treated with lorazepam. The patient recovered, returned to baseline status in 2 days, and was later transferred back to the nursing home. DISCUSSION: We believe that in both cases, serotonin syndrome was precipitated by risperidone in combination with SSRI antidepressants. A literature search indicated one report of serotonin syndrome with a combination of risperidone and paroxetine. CONCLUSIONS: An objective causality assessment revealed that the adverse drug event was probable in the first patient and definite in the second patient. We caution clinicians treating elderly patients with combined risperidone and SSRIs to include serotonin syndrome in differential diagnosis if the patient is showing signs of increasing agitation with escalating doses of risperidone.

Sign in / Sign up

Export Citation Format

Share Document